T
Tevogen Bio
Biotech & Life Sciences · Metuchen, United States · Founded 2020 · Public via SPAC 2023
Clinical-stage specialty immunotherapy company leveraging ExacTcellTM technology platform to harness the power of CD8+ cytotoxic T lymphocytes to develop off-the-shelf, precision T cell therapies for… MoreLess
Tevogen Bio is a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T-cell therapies for the treatment of infectious diseases and cancer. The firm's proprietary ExacTcell platform harnesses the power of cytotoxic T lymphocytes (CTLs) to create scalable and rapidly producible treatments.
The company's approach focuses on developing therapeutic products that are designed to be accessible and affordable, targeting a broad range of patients. Tevogen Bio is currently advancing its pipeline of product candidates for various viral infections and cancers, leveraging its expertise in cell and gene therapy. As a publicly-traded entity, its business model is centered on the research, clinical development, and eventual commercialization of its immunotherapies.
Keywords: immunotherapy, T-cell therapy, oncology, infectious diseases, biotechnology, cell therapy, gene therapy, clinical-stage, cytotoxic T lymphocytes, ExacTcell
Talent graph
Tevogen Bio's talent
Source: Dealroom Talent Intelligence.
Investors
2 investors on Tevogen Bio's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Tevogen Bio has talent and traffic
team presence
across markets
Patent intelligence
$167k patent portfolio · 3 active families
Where Tevogen Bio concentrates vs peers
Each axis is a top-10 topic across Tevogen Bio and its closest peers. #1 = 100, #10 = 10, absent = 0.
Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.
Market sentiment
What the market is saying about Tevogen Bio
An AI-synthesized read of the highest-engagement posts about Tevogen Bio on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Tevogen Bio on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.